Sandoz confirms strategic commitment to drive access to medicines in Japan, with plan to double business by 2022
Feb 07, 2017
Japanese generic market set to expand rapidly, driven by government commitment to achieving sustainable high-quality healthcare
Sandoz Japan plans 70 new launches over next six years, which will account for ~40% of total sales by 2022
Growth drivers will include oncology, CNS and biosimilars
Tokyo, February 8, 2017– Sandoz plans to double sales in Japan over the 2015 to 2022 period, as part of its long-term strategic plan to help drive access to hiqh-quality medicines in the Japanese market.
Against the background of the Japanese government’s plan to raise the share of generic medicines to 80% by 2020, Sandoz is looking to accelerate the launch of new products in Japan over the coming years with a focus on oncology, central nervous system medications, and biosimilars.
Speaking ahead of a media conference in Tokyo today, Sandoz CEO and Division Head Richard Francis said: “Our Purpose at Sandoz is to increase patient access by helping more people around the world obtain high quality medicines at affordable prices. To deliver on this goal of making access happen, we need to focus our efforts on the markets where we can really make a difference for the patients we serve.”
Richard Francis added: “Japan is a priority market for Sandoz. It combines a real and growing need to increase patient access to affordable high-quality medicines with a government that is committed to actively driving the market share of high-quality generic medicines. We aim to play an increasingly important role in helping to achieve that goal and keep the Japanese healthcare systems sustainable in the face of an ageing population and the rising cost of non-communicable diseases such as cardiovascular disorders, cancers, chronic respiratory ailments and diabetes.”
For Sandoz, improving access entails helping to get the right products to the right people at the right cost, helping patients better understand the medicines they are being prescribed, and support capacity building for the doctors who eventually prescribe the treatments. A study1 commissioned by Sandoz last year in key markets worldwide identified three key major concerns the Japanese public and the country’s healthcare professionals share with regard to access in Japan: a rapidly ageing population, the growing prevalence of lifestyle-related diseases and the rising cost of treating chronic non-communicable diseases.
Sandoz Japan Country Head Jason Hoffe said Sandoz planned to grow its business consistently above the market over the next six years, driven by a total of 70 new launches, which would account for approximately 40% of total sales by 2022.
In addition to new launches, he said the above-market growth rate would be driven by strong customer relationships and a stable and secure supply chain. Key growth areas for Sandoz Japan will include oncology, CNS (central nervous system) and biosimilars, in which Sandoz is already the recognized pioneer and global market leader.
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of USD 10.1 billion. In 2016, our products reached well over 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.